Table 2.
Crude and adjusted estimates of the effect of baseline FIB-4 score on hospitalization and in-hospital mortality among patients at risk of Non-Alcoholic Fatty Liver Disease diagnosed with COVID-19 (N = 373)
| Hospitalized | Hospitalization | p value | Died | In-hospital mortality | p value | |
|---|---|---|---|---|---|---|
| Crude effect | ||||||
| FIB-4 score* | ||||||
| Low | 63/285 | 1.00 (reference) | 16/285 | 1.00 (reference) | ||
| Intermediate | 19/60 | 1.63 (1.13–2.35) | 0.01 | 5/60 | 1.53 (0.34–6.94) | 0.58 |
| High | 9/28 | 1.67 (1.14–2.45) | 0.01 | 6/28 | 4.59 (1.46–14.44) | 0.01 |
| Effect adjusted for DM2 and CKD** | ||||||
| FIB-4 score* | ||||||
| Low | 63/285 | 1.00 (reference) | 16/285 | 1.00 (reference) | ||
| Intermediate | 19/60 | 1.67 (1.06–2.64) | 0.03 | 5/60 | 1.52 (0.37–6.34) | 0.56 |
| High | 9/28 | 0.96 (0.84–1.10) | 0.54 | 6/28 | 2.22 (1.20–4.12) | 0.01 |
*For patients between age 35 years old and less than 65, cutoffs were < 1.30, 1.30–2.67 and > 2.67 for low, intermediate and high risk of fibrosis, respectively. For patients 65 years and older, the cutoffs used were < 2, 2–2.67 and > 2.76 for low, intermediate and high risk of fibrosis, respectively
**Co-variate selection based on direct acyclic graphs presented in Supplemental Figure 2